This clinical trial is focused on studying treatments for severe respiratory illnesses, including severe influenza, severe and moderate COVID-19 infection, and severe community-acquired pneumonia (CAP). The trial aims to find out how different treatments can improve the health outcomes of patients who are seriously ill and admitted to the hospital, especially those in intensive care units (ICUs). The main goal is to see if these treatments can reduce the number of deaths within 90 days for patients with severe CAP and during a pandemic, to improve outcomes for those with acute illnesses due to suspected or confirmed pandemic infections.
The study involves several medications, including baricitinib, piperacillin sodium, tazobactam sodium, tocilizumab, amoxicillin sodium, clavulanic acid, azithromycin, levofloxacin, erythromycin lactobionate, baloxavir marboxil, oseltamivir, moxifloxacin, dexamethasone, imatinib, ceftriaxone, hydrocortisone, and roxithromycin. Some patients may receive a placebo, which is a substance with no active medication, to compare the effects of the actual treatments. The trial is designed to adapt and change based on the results as they come in, which helps researchers find the best treatment options more quickly.
Participants in the study will receive one or more of these treatments, and their health will be monitored over time to see how they respond. The study will look at various outcomes, such as survival rates, the length of time spent in the ICU, and the number of days patients are free from needing a ventilator or other organ support. The trial is expected to continue until March 2026, with the aim of providing valuable information on how to best treat these serious respiratory conditions.



Belgium
Croatia
Czechia
Estonia
France
Germany
Ireland
Italy
Portugal
Romania
Slovenia
Spain
The Netherlands